ISIS chief Abu Bakr al-Baghdadi killed in US raid in Syria: Trump

Dubai, July 6: In an attempt to make a comeback in the tourism sector amidst managing covid-19 crisis, Dubai is all set to welcome holiday-makers from foreign countries from July 7.

It said those entering would have to present certificates to show they had recently tested negative for the coronavirus or would undergo tests on arrival at Dubai airports.

Reassuring tourists of several comprehensive measures to prevent the transmission of the pandemic, Dubai Tourism urged global travellers to make the city that boasts world class health and safety standards "a must-visit destination."

Dubai Tourism hosted a virtual forum for stakeholders and partners to share its industry outlook ahead of the city's reopening to international tourists.

The forum, which was attended by nearly 2,000 key executives from the aviation, travel and hospitality sectors and across tourism touch-points, provided a first-hand insight into current and post-pandemic strategies that will help accelerate tourism momentum and position Dubai as a safe global destination.

Helal Saeed Almarri, director general, Dubai Tourism, said that the city has put in place a robust strategy to manage the pandemic with the key priority being to safeguard the health and well-being of citizens, residents and guests.

Dubai, which saw a 5.1 per cent in tourist traffic to 16.73 million in 2019, remains top of mind for travellers and ranks high in global Internet search rankings for tourist destinations.

Dubai Tourism has launched marketing activities designed to convey positive messages about travel in today's environment, Dubai's preparedness, high standards of quality and safety, unique experiences that await visitors and also address traveller concerns across every touch-point in their journey.

The forum highlighted the preventive measures taken so far against Covid-19 that have further elevated the UAE's standing as one of the world's safest countries. The UAE is globally ranked No.3 in testing per million of population. It was also ranked No.3 in an international survey that assessed satisfaction with governments' response to the pandemic.

Over 350 influencers were also deployed to take the Dubai story in 14 different languages to a global audience spanning 18 markets, which yielded over 21 million engagements across multiple social media platforms.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.